Read by QxMD icon Read

Clinical Breast Cancer

Savaş Serel, Zeynep Yasavur Tuzlalı, Zehra Akkaya, Çağlar Uzun, Burak Kaya, Sancar Bayar
OBJECTIVE: Mastectomy is known to effect body posture after a change in the center of gravity of women due to a missing breast. Although previous studies on short-term postural changes in mastectomy patients using photogrammetry or Moiré topography suggested ipsilateral inclination of the trunk, our clinical observations during breast reconstruction surgeries indicated a contralateral shoulder elevation in women with unilateral mastectomy. Because the change in body posture can affect spinal alignment, we aimed to evaluate the long-term physical effects of unilateral mastectomy on spine deformity by radiographic examination...
October 26, 2016: Clinical Breast Cancer
Chinedum O Ojinnaka, Wen Luo, Marcia G Ory, Darcy McMaughan, Jane N Bolin
INTRODUCTION: Early-stage breast cancer can be surgically treated by using mastectomy or breast-conserving surgery and adjuvant radiotherapy, also known as breast-conserving therapy (BCT). Little is known about the association between racial residential segregation, year of diagnosis, and surgical treatment of early-stage breast cancer, and whether racial residential segregation influences the association between other demographic characteristics and disparities in surgical treatment...
October 19, 2016: Clinical Breast Cancer
Naghmeh Isfahanian, Thuraya Al-Hajri, Horia Marginean, Lynn Chang, Jean-Michel Caudrelier
PURPOSE: The standard dose of postlumpectomy radiotherapy (RT) for ductal carcinoma in situ (DCIS) is 50 Gy in 25 fractions using conventional fractionation (CF). However, in invasive carcinoma, hypofractionation (HF) with 40 to 42.6 Gy in 15 to 16 fractions has largely become a standard of care. The purpose of this study was to review the management of postlumpectomy DCIS in terms of RT dose-fractionation and its impact on local recurrence (LR), in one of the largest Canadian academic centers...
October 19, 2016: Clinical Breast Cancer
Elena Leinert, Susanne Singer, Wolfgang Janni, Nadia Harbeck, Tobias Weissenbacher, Brigitte Rack, Doris Augustin, Arthur Wischnik, Marion Kiechle, Johannes Ettl, Visnja Fink, Lukas Schwentner, Martin Eichler
BACKGROUND: Elderly breast cancer patients are affected by poorer quality of life (QoL) compared to younger patients. Because QoL has a relevant impact on guideline-adherent treatment, elderly breast cancer patients are often undertreated, especially with regard to adjuvant chemotherapy, and overall survival is decreased. Thus, understanding the impact of chemotherapy on QoL in elderly patients is crucial. This study compared QoL in patients aged < 65 years and 65 to 70 years receiving adjuvant chemotherapy as a secondary outcome in the prospective randomized multicenter ADEBAR trial...
October 19, 2016: Clinical Breast Cancer
Christine Rodhouse, Iman Soliman, Mariah Cruse, Joseph Kastrenakes, C J Augustine, Alexis Ludy, Eric Reintgen, Alexa Hoadley, Divya Desai, Minh Nguyen, Douglas Scott Reintgen
INTRODUCTION: With the advent and proliferation of breast cancer screening programs, more women are being diagnosed with mammographic abnormalities that require tissue diagnosis. If imaged-guided biopsy is not possible or previous image-guided biopsies reveal pathologies that require more extensive surgery, guided excisional biopsy/lumpectomy may be necessary. METHODS: Fifteen women were enrolled in the study of the feasibility of off-site or day-before wire-localization excisional biopsy of the breast with mammographic abnormalities...
October 19, 2016: Clinical Breast Cancer
So Hee Kim, Hee Jung Shin, Ki Chang Shin, Eun Young Chae, Woo Jung Choi, Joo Hee Cha, Hak Hee Kim
PURPOSE: To evaluate the diagnostic performance of fused diffusion-weighted imaging (DWI) using T1-weighted imaging (T1WI) for axillary nodal staging in patients with early breast cancer (stage I or II). MATERIALS AND METHODS: We enrolled 149 axillae in 147 consecutive patients who performed preoperative breast magnetic resonance imaging (MRI) and definitive surgery. All patients underwent T2-weighted imaging (T2WI), fused DWI using T1WI, and non-fat-suppressed (non-FS) T1WI...
October 19, 2016: Clinical Breast Cancer
Antonio Marrazzo, Giuseppe Damiano, Pietra Taormina, Salvatore Buscemi, Attilio Ignazio Lo Monte, Emilia Marrazzo
BACKGROUND: The role of axillary surgery for early breast carcinoma treated with conservative surgery and radiotherapy is currently the subject of considerable investigation. Recent studies have supported the noninferiority of avoiding axillary surgery in terms of overall survival when sentinel lymph node biopsy (SLNB) presents ≤ 2 positive lymph nodes, thus sparing the patients from complications. There are some ongoing studies investigating the possibility of omitting SLNB. Axillary study seems to be sufficiently replaced by SLNB for staging the disease...
October 18, 2016: Clinical Breast Cancer
Anita Muthukaruppan, Annette Lasham, Kathryn J Woad, Michael A Black, Cherie Blenkiron, Lance D Miller, Gavin Harris, Nicole McCarthy, Michael P Findlay, Andrew N Shelling, Cristin G Print
BACKGROUND: Molecular markers have transformed our understanding of the heterogeneity of breast cancer and have allowed the identification of genomic profiles of estrogen receptor (ER)-α signaling. However, our understanding of the transcriptional profiles of ER signaling remains inadequate. Therefore, we sought to identify the genomic indicators of ER pathway activity that could supplement traditional immunohistochemical (IHC) assessments of ER status to better understand ER signaling in the breast tumors of individual patients...
September 13, 2016: Clinical Breast Cancer
Karen A Cadoo, Patrick G Morris, Elizabeth P Cowell, Sujata Patil, Clifford A Hudis, Heather L McArthur
INTRODUCTION: The benefit of adjuvant trastuzumab with chemotherapy is well established for women with higher risk human epidermal growth factor receptor 2-positive (HER2(+)) breast cancer. However, its role in older patients with smaller, node-negative tumors is less clear. We conducted a retrospective, sequential cohort study of this population to describe the impact of trastuzumab on breast cancer outcomes and cardiac safety. PATIENTS AND METHODS: Women ≥ 55 years with ≤ 2 cm, node-negative, HER2(+) breast cancer were identified and electronic medical records reviewed...
December 2016: Clinical Breast Cancer
Denise A Yardley, James Reeves, E Claire Dees, Cynthia Osborne, Devchand Paul, Foluso Ademuyiwa, Hatem Soliman, Troy Guthrie, Jay Andersen, Lea Krekow, Janak Choksi, Brooke Daniel, Michael Danso, Anne Favret, Sanjay Oommen, Adam Brufsky, Jane L Bromund, Yong Lin, Ayman B Ibrahim, Paul D Richards
BACKGROUND: Use of antiangiogenic agents in treatment of metastatic breast cancer (MBC) remains controversial. We evaluated the efficacy and safety of ramucirumab and eribulin versus eribulin alone as third- to fifth-line therapy in women with advanced breast cancer. PATIENTS AND METHODS: In this randomized (1:1), open-label, phase II study, US women aged 18 years or older with 2 to 4 previous chemotherapy regimens for locally recurrent or MBC, previous anthracycline and taxane treatment, and Eastern Cooperative Oncology Group performance status of 0 or 1 received ramucirumab with eribulin or eribulin alone in 21-day cycles (eribulin 1...
December 2016: Clinical Breast Cancer
Woo Jung Choi, Joo Hee Cha, Hak Hee Kim, Hee Jung Shin, Eun Young Chae
BACKGROUND: The objective of the study was to compare the accuracy of different magnetic resonance (MR) sequences for measuring tumor size and to evaluate whether the imaging and histopathologic features affect the accuracy of the tumor size estimation on the MR sequence. PATIENTS AND METHODS: Eight hundred women were included. The maximum diameter of the tumor was measured on T2-weighted (T2W) sequences, early-subtracted dynamic contrast-enhanced (DCE) T1-weighted (T1W) sequences, and maximal intensity projection (MIP) reconstructions...
December 2016: Clinical Breast Cancer
Shaan Dudani, Sasha Mazzarello, John Hilton, Brian Hutton, Lisa Vandermeer, Ricardo Fernandes, Mohammed F K Ibrahim, Stephanie Smith, Habeeb Majeed, Khalid Al-Baimani, Jean-Michel Caudrelier, Risa Shorr, Mark Clemons
The incidence of leptomeningeal carcinomatosis in breast cancer patients (LC-BC) is increasing. Despite significantly affecting patient quality of life (QoL) and overall survival (OS), little is known about its optimal management. A systematic review of treatment strategies for LC-BC was performed. EMBASE, Ovid Medline, Pubmed, and the Cochrane Central Register of Controlled Trials were searched from 1946 to 2015 for trials reporting on treatments for LC-BC. All treatment modalities and study types were considered...
December 2016: Clinical Breast Cancer
Qijia Xuan, Kun Gao, Ying Song, Shu Zhao, Lina Dong, Zhongbai Zhang, Qingyuan Zhang, Jingxuan Wang
PURPOSE: The purpose of this study was to evaluate the differences in stage upon diagnosis, adherence to adjuvant treatment, and recurrence between rural and urban patients with early breast cancer. METHODS: This retrospective study included 3640 patients with primary breast cancer recruited from 2000 to 2009. Patients who developed recurrence or metastasis were verified by adequate diagnostic imaging modalities and pathology. The χ(2) test was used to compare groups with respect to variables (recurrence and clinicopathologic features)...
December 2016: Clinical Breast Cancer
Kimihiro Tanaka, Eriko Tokunaga, Yuka Inoue, Nami Yamashita, Hiroshi Saeki, Shinji Okano, Hiroyuki Kitao, Eiji Oki, Yoshinao Oda, Yoshihiko Maehara
BACKGROUND: The association between Axl and vimentin protein expression has been observed in several cell lines. However, the clinical importance of Axl and vimentin expression in breast cancer have not been fully determined. PATIENTS AND METHODS: The expressions of Axl and vimentin were evaluated by immunohistochemistry in a total of 343 patients with invasive ductal carcinoma. The relationships between expression of Axl and vimentin and clinicopathologic characteristics and prognosis were analyzed...
December 2016: Clinical Breast Cancer
Elena Navarro-Rodríguez, Nélida Díaz-Jiménez, Juan Ruiz-Rabelo, Irene Gómez-Luque, Guillermo Bascuñana-Estudillo, Pilar Rioja-Torres, Manuela Torres-Lorite, Rubén Ciria-Bru, Marina Álvarez-Benito, Javier Briceño-Delgado
INTRODUCTION: The objective of our study was to assess recurrence after negative sentinel lymph node biopsy (SLNB) and to determine the risk factors related to local and distant recurrence in this group of patients. MATERIALS AND METHODS: We conducted a prospective observational study from 2006 to 2011. It included 607 patients with early-stage breast cancer and negative SLNB with a 5-year follow-up period. RESULTS: The disease-free survival rate was 98...
December 2016: Clinical Breast Cancer
Susan R Harris
Spontaneous rib fracture after treatment for primary breast cancer is not uncommon. Although metastatic disease accounts for about 30% of spontaneous rib fractures and should constitute the first line of diagnostic investigation, other possible contributors include primary osteoporosis or secondary osteoporosis resulting from cancer treatments. Chemotherapy-induced menopause, aromatase inhibitors, radiation therapy, and long-term bisphosphonate use can all contribute to bone fragility, including spontaneous rib fractures in the latter 3...
December 2016: Clinical Breast Cancer
Jocelyn S Chapman, Erika Roddy, Anna Panighetti, Shelley Hwang, Beth Crawford, Bethan Powell, Lee-May Chen
BACKGROUND: Women with breast cancer who carry BRCA1 or BRCA2 mutations must also consider risk-reducing salpingo-oophorectomy (RRSO) and how to coordinate this procedure with their breast surgery. We report the factors associated with coordinated versus sequential surgery and compare the outcomes of each. PATIENTS AND METHODS: Patients in our cancer risk database who had breast cancer and a known deleterious BRCA1/2 mutation before undergoing breast surgery were included...
December 2016: Clinical Breast Cancer
Fahad M Iqbal, Anjali Bhatnagar, Raghavan Vidya
No abstract text is available yet for this article.
December 2016: Clinical Breast Cancer
Mark Abramovitz, Casey Williams, Sibylle Loibl, Brian Leyland-Jones
The dual small molecule tyrosine kinase inhibitor lapatinib blocks both human epidermal growth factor receptor (HER-1) and human epidermal growth factor receptor 2 (HER-2) tyrosine kinase activity by binding reversibly to the ATP-binding site of the receptor's intracellular domain. Lapatinib, in combination with capecitabine, has been approved in 2007 for the treatment of patients with advanced HER-2(+) breast cancer upon progressive disease following standard chemotherapy. Approval was also extended to the treatment of postmenopausal women with advanced hormone receptor (HR)-positive and HER-2-positive breast cancer in 2010...
December 2016: Clinical Breast Cancer
Vincent Varilla, Pamela Taxel, Susan Tannenbaum
No abstract text is available yet for this article.
December 2016: Clinical Breast Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"